International Journal of Endocrinology / 2013 / Article / Tab 2

Clinical Study

Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)

Table 2

Changes in anthropometric measurements and blood pressure.

ParametersGroup0 month12 monthsP-valueDifferenceP-value

Body mass index (kg/m2)T 0.875
L 0.398 0.447
Waist circumference (cm)T 0.247
L 0.091 0.310
Hip circumference (cm)T 0.500
L 0.655 0.754
Systolic blood pressure (mmHg)T 0.045
L 0.046 0.933
Diastolic blood pressure (mmHg)T 0.032
L 0.116 0.446
Pulse (beats/min)T 0.397
L 0.273 0.397

Data are presented as mean SD. Parameters at 0 and 12 months of treatment were compared by Wilcoxon's matched-pair signed-rank test. Differences are shown as [value at 12 months − value at 0 month]. Differences between groups (telmisartan (T) versus losartan (L)) were compared by Mann-Whitney test.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.